Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalfermin PK interaction with oral contraceptives
NCT06188026Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nn9500 in Nonalcoholic steatohepatitis (NASH), sponsored by Novo Nordisk. Primary endpoints: Area under the ethinylestradiol plasma concentration-time curve at Day 38 and Area under the levonorgestrel plasma concentration-time curve at Day 38. Started Dec 2023; status: completed.
02
Drugs
nn9500
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06188026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188026.